Stevanato Group S.p.A. (STVN)
| Market Cap | 4.45B |
| Revenue (ttm) | 1.39B |
| Net Income (ttm) | 164.19M |
| Shares Out | 273.00M |
| EPS (ttm) | 0.60 |
| PE Ratio | 27.20 |
| Forward PE | 23.16 |
| Dividend | $0.06 (0.39%) |
| Ex-Dividend Date | Jun 5, 2025 |
| Volume | 811,273 |
| Open | 16.00 |
| Previous Close | 16.18 |
| Day's Range | 15.78 - 16.49 |
| 52-Week Range | 12.89 - 28.00 |
| Beta | 0.62 |
| Analysts | Buy |
| Price Target | 25.67 (+57.58%) |
| Earnings Date | May 7, 2026 |
About STVN
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injector... [Read more]
Financial Performance
In 2025, Stevanato Group's revenue was 1.19 billion, an increase of 7.45% compared to the previous year's 1.10 billion. Earnings were 139.84 million, an increase of 18.73%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for STVN stock is "Buy." The 12-month stock price target is $25.67, which is an increase of 57.58% from the latest price.
News
Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Strong growth in high-value solutions and biologics drove margin expansion and record revenues in 2025, with further gains expected in 2026. Major capacity investments in sterile cartridges and drug delivery systems support long-term growth, while new plants are set to deliver high profitability.
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group Earnings Call Transcript: Q4 2025
Fiscal 2025 saw strong revenue and margin growth, led by high-value solutions and robust GLP-1 demand. 2026 guidance anticipates continued BDS growth, margin expansion, and high-value solutions reaching up to 48% of revenue, despite currency and engineering headwinds.
Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group Transcript: Jefferies London Healthcare Conference 2025
A leading provider of injection-related pharmaceuticals is expanding global capacity and focusing on high-value solutions for biologics and GLP-1 drugs. Revenue and EBITDA have more than doubled, with robust demand, long-term contracts, and heavy investment in R&D and integrated systems supporting growth. Several hundred molecules are being filed with clients.
Stevanato Group Transcript: Wolfe Research Healthcare Conference 2025
Major CapEx investments and a shift to high-value products are driving growth, especially in biologics and GLP-1s. Policy clarity and reshoring support future U.S. expansion, while engineering segment efficiency is improving despite order timing delays.
Stevanato Group Earnings Call Transcript: Q3 2025
Q3 revenue grew 9% year-over-year, led by high-value solutions and strong BDS segment growth. Margins expanded, guidance for 2025 was reiterated, and capacity investments continue to support robust demand in biologics and ready-to-use products.
Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Participate in Upcoming Investor Conferences
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group Expands Drug Delivery Systems Capacity to Strengthen Global Integrated Offerings
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology a...
Stevanato Group Transcript: Bank of America Global Healthcare Conference 2025
The company is executing a global expansion focused on high-value solutions, with major investments in new manufacturing sites and strong multi-year customer partnerships. Financial performance is robust, driven by margin expansion and growth in high-value products, while operational improvements and market trends in biologics and drug delivery systems support a positive outlook.
Stevanato Group Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Capacity expansion in Italy and the U.S. is on track, supported by long-term contracts and a focus on high-value products with strong gross margins. Biologics and GLP-1s drive growth, while inventory normalization and engineering improvements support future profitability. Fishers and Latina facilities are key to long-term revenue and margin expansion.
Stevanato Group Earnings Call Transcript: Q2 2025
Q2 2025 saw 8% revenue growth, margin expansion, and strong BDS segment performance, offsetting engineering declines. High-value solutions rose to 42% of revenue, and guidance for 2025 is reiterated, with ongoing investments and market tailwinds supporting long-term growth.
Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and lif...
Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group Transcript: Jefferies Global Healthcare Conference 2025
The company is experiencing strong growth in biologics and injectables, with major capacity expansions in the U.S. and Italy supporting double-digit growth targets. Proprietary device innovation and robust demand are driving revenue, while risk management and operational optimization ensure resilience.
Stevanato Group Transcript: 45th Annual William Blair Growth Stock Conference
With a 75-year legacy, the group has doubled revenue in five years and is investing over EUR 1 billion to expand global capacity, focusing on high-value products for biologics and injectables. Q1 2024 showed 9% growth, and major investments are now contributing to revenue.
Stevanato Group Earnings Call Transcript: Q1 2025
Q1 2025 saw 9% revenue growth and margin expansion, led by high-value solutions and strong BDS segment performance. Guidance for 2025 is reiterated, with tariffs expected to have a limited impact and ongoing investments in Fishers and Latina supporting future growth.
Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group Transcript: KeyBanc Annual Healthcare Forum 2025
U.S. listing enabled benchmarking and growth, with a focus on pharma and integrated solutions. Major expansions in Indiana and Latina are progressing, driven by strong demand and multi-year contracts. High-value products and biologics are key growth areas, while operational improvements and market normalization are underway.